{"id":"krt-232","safety":{"commonSideEffects":[{"rate":"30%","effect":"Fatigue"},{"rate":"20%","effect":"Nausea"},{"rate":"15%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL3125702","moleculeType":"Small molecule","molecularWeight":"568.56"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"KRT-232 is a potent and selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which play a critical role in the progression of the cell cycle.","oneSentence":"Inhibits CDK4/6","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:58:21.441Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myeloproliferative neoplasms"}]},"trialDetails":[{"nctId":"NCT04190550","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-04","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","enrollment":24},{"nctId":"NCT03041688","phase":"PHASE1","title":"Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-08","conditions":"Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":58},{"nctId":"NCT03031730","phase":"PHASE1","title":"Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-14","conditions":"Plasmacytoma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":35},{"nctId":"NCT03107780","phase":"PHASE1","title":"Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-07-09","conditions":"Glioblastoma, Gliosarcoma, MGMT-Unmethylated Glioblastoma","enrollment":32},{"nctId":"NCT06479135","phase":"PHASE3","title":"Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib","status":"RECRUITING","sponsor":"Kartos Therapeutics, Inc.","startDate":"2024-06-03","conditions":"Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis","enrollment":600},{"nctId":"NCT03217266","phase":"PHASE1","title":"Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-20","conditions":"Resectable Soft Tissue Sarcoma, Soft Tissue Sarcoma","enrollment":39},{"nctId":"NCT05797831","phase":"PHASE2, PHASE3","title":"Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer","status":"RECRUITING","sponsor":"Kartos Therapeutics, Inc.","startDate":"2023-07-17","conditions":"Endometrial Cancer","enrollment":268},{"nctId":"NCT05705466","phase":"PHASE1, PHASE2","title":"Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"Kartos Therapeutics, Inc.","startDate":"2023-06","conditions":"Non Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT04113616","phase":"PHASE1, PHASE2","title":"An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)","status":"TERMINATED","sponsor":"Kartos Therapeutics, Inc.","startDate":"2019-09-25","conditions":"Relapsed or Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)","enrollment":70},{"nctId":"NCT05027867","phase":"PHASE2","title":"KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Kartos Therapeutics, Inc.","startDate":"2021-12-06","conditions":"Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage","enrollment":3},{"nctId":"NCT03662126","phase":"PHASE2, PHASE3","title":"KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment","status":"UNKNOWN","sponsor":"Kartos Therapeutics, Inc.","startDate":"2019-01-15","conditions":"Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)","enrollment":385},{"nctId":"NCT03787602","phase":"PHASE1, PHASE2","title":"Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma","status":"UNKNOWN","sponsor":"Kartos Therapeutics, Inc.","startDate":"2019-03-19","conditions":"Merkel Cell Carcinoma","enrollment":115},{"nctId":"NCT04669067","phase":"PHASE1, PHASE2","title":"TL-895 and KRT-232 Study in Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Telios Pharma, Inc.","startDate":"2021-03-31","conditions":"Acute Myeloid Leukemia","enrollment":18},{"nctId":"NCT04502394","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL","status":"UNKNOWN","sponsor":"Kartos Therapeutics, Inc.","startDate":"2021-02-23","conditions":"Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma","enrollment":84},{"nctId":"NCT04640532","phase":"PHASE1, PHASE2","title":"KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF","status":"UNKNOWN","sponsor":"Kartos Therapeutics, Inc.","startDate":"2020-11-17","conditions":"Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis","enrollment":116},{"nctId":"NCT04485260","phase":"PHASE1, PHASE2","title":"An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib","status":"UNKNOWN","sponsor":"Kartos Therapeutics, Inc.","startDate":"2021-01-28","conditions":"Myelofibrosis","enrollment":36},{"nctId":"NCT04878003","phase":"PHASE2","title":"Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis","status":"UNKNOWN","sponsor":"Kartos Therapeutics, Inc.","startDate":"2021-04-13","conditions":"Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV-MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)","enrollment":52},{"nctId":"NCT04835584","phase":"PHASE1, PHASE2","title":"KRT-232 and TKI Study in Chronic Myeloid Leukemia","status":"RECRUITING","sponsor":"Kartos Therapeutics, Inc.","startDate":"2021-05-07","conditions":"Chronic Myeloid Leukemia","enrollment":109},{"nctId":"NCT03669965","phase":"PHASE2","title":"KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera","status":"UNKNOWN","sponsor":"Kartos Therapeutics, Inc.","startDate":"2019-01-15","conditions":"Polycythemia Vera","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["navtemadlin"],"phase":"phase_2","status":"active","brandName":"KRT-232","genericName":"KRT-232","companyName":"Kartos Therapeutics, Inc.","companyId":"kartos-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits CDK4/6 Used for Myeloproliferative neoplasms.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":5,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}